R
Rani Therapeutics
Develops bio-therapeutics technology for the oral delivery of large drug molecule
About Rani Therapeutics
Rani Therapeutics is a pioneering company in the healthcare sector, focusing on the innovative delivery of biologic drugs. Biologics are complex medications made from living organisms, often used to treat chronic diseases. Traditionally, these drugs are administered through injections, which can be painful and inconvenient for patients. Rani Therapeutics has developed a groundbreaking technology that converts these injectable drugs into oral capsules, making it easier for patients to take their medication.
Read full description
The company operates in the biopharmaceutical market, targeting a wide range of chronic conditions such as diabetes, rheumatoid arthritis, multiple sclerosis, and more. Their primary clients include healthcare providers, pharmaceutical companies, and patients suffering from these chronic diseases. By offering an alternative to injections, Rani Therapeutics aims to improve patient compliance and overall quality of life.
Rani Therapeutics' business model revolves around the commercialization of their unique oral delivery platform. They generate revenue through partnerships with pharmaceutical companies, licensing their technology, and eventually selling their proprietary capsules. The company has conducted extensive preclinical studies, demonstrating that their oral capsules are as effective as traditional subcutaneous (under the skin) injections.
In summary, Rani Therapeutics is revolutionizing the way biologic drugs are delivered, making treatment more accessible and less invasive for millions of patients. Their innovative approach has the potential to transform the biopharmaceutical landscape and significantly impact patient care.
At a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- San Jose, United States
- Listing
- IPO 2021
- Employees
- 100
- Open positions
- 4
- Dealroom signal
- 48.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Patient Care, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Rani Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $20M | — | Chardan · H.C. Wainwright | ↗ |
| POST IPO DEBTDebt | Oct 2025 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $4.1M | +152.8% | −$37M | -886.2% |
| 2025 | $1.6M | +58.9% | −$37M | -2240.2% |
| 2024 | $1M | — | −$47M | -4553.4% |
| 2023 | $0 | — | −$62M | — |
| 2022 | $0 | -100% | −$62M | — |
| 2021 | $2.7M | +488.1% | −$52M | -1895.8% |
| 2020 | $462K | — | −$16M | -3439.8% |
Growth signals
Latest recorded traffic for Rani Therapeutics is 4.6K monthly website visits, down 2.1% over the last three months. Rani Therapeutics's team grew 7.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Shire
Series A2 investors entered at this stage
Incube Ventures
VentureHealth
Series B and later15 investors entered at this stage
Novartis
Western Life Sciences Venture Fund
Buttonwood Capital
AstraZeneca
Virtus Inspire Ventures
Ping An Ventures
KPC Pharmaceuticals
GV
Cathay Venture- CICrystal Horizon Investments
- PFPacific Venture Opportunity Fund
- PIPinemount Investment
Bossa Invest- CHChardan
H.C. Wainwright
Other known investors5 additional known investors
Anomaly
Invus
RA Capital Management
Samsara BioCapital- SFSpecial Situations Funds
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rani Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rani Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.